A study of pembrolizumab and usual treatment for cervical cancer (The Papaya Study)
Cancer type:
Cervical cancer
Status:
Results
Phase:
Phase 1
This study looked at whether pembrolizumab could improve treatment for cancer of the cervix.
More about this trial
Doctors often treat cervical cancer with a combination of chemotherapy and radiotherapy. This is called chemoradiation. It is standard treatment for cervical cancer.
But sometimes the cancer continues to grow. So, researchers are looking for ways to improve treatment. In this study they looked at a drug called pembrolizumab.
Pembrolizumab is a type of immunotherapy It works by helping the immune system to recognise and attack cancer cells.
The main aims of this study were to:
- see if adding pembrolizumab to standard treatment keeps the cancer under control for longer
- learn more about the side effects
Summary of results
It was difficult to get enough women to join the trial. So the trial was never finished and there are no results available.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Chief Investigator
Dr Susan Lalondrelle
Supported by
Biomedical Research Centre (BRC)
Merck, Sharpe & Dohme
Royal Marsden NHS Foundation Trust
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last review date
CRUK internal database number:
15406
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
